Polaryx Therapeutics, Inc. Net Income increased by 49.6% to -$2.54M in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Consistent growth in net income is the primary driver of long-term stock price appreciation and dividend capacity.
The 'bottom line' profit of the company after all expenses, including interest and taxes, have been deducted from total...
This is the standard metric for calculating Earnings Per Share (EPS) and Price-to-Earnings (P/E) ratios.
net_income| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | -$5.05M | -$2.54M |
| QoQ Change | — | +49.6% |
| YoY Change | — | +49.6% |
| Segment | Q1 '25 | Q1 '26 |
|---|---|---|
| Lysosomal Storage Disorders | -$5.05M | -$2.54M |
| Total | -$5.05M | -$2.54M |